Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455672 | 0.87 | GABRA1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL30528651 | 0.82 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL338177 | 0.82 | GABRA1 (0.38) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL1538580 | 0.78 | TRPA1 (0.39) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL29118636 | 0.77 | TAAR1 (0.37) | GABRA1GABRB2TSHR | |
| SCHEMBL5317677 | 0.76 | GABRA1 (0.56) | GABRA1GABRB2TSHR | |
| SCHEMBL7827553 | 0.76 | GABRA1 (0.39) | GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL18550415 | 0.76 | ALDH1A1 (0.35) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL5852660 | 0.74 | TAAR1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL1538927 | 0.74 | ALDH1A1 (0.36) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378522-B2 | Such as 6-(4-Acetamidophenoxy)-5-(N-benzyl-N-methylaminomethyl)-1-(2',6'-difluorobenzyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid-ethyl ester; rapid effectiveness, bioavailability; low cost, simple synthesis | ZENTARIS AG (DE) | 2008-05-27 | — | — | US | disclosed |
| US-20050004127-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | AETERNA ZENTARIS GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| US-6790858-B2 | HIGH EFFECTIVENESS AND HIGH ORAL BIOAVAILABILITY; FOR EXAMPLE, 6-(4-ACETAMIDOPHENYL)-3-ISOBUTYRYL-5-(N-BENZYL-N-METHYLAMINOMETHYL)-1-(2',6'-DIFLUOROBENZYL)-1,4-DIHYDRO-4-OXOQUINOLINE | ZENTARIS AG (DE) | 2004-09-14 | — | — | US | disclosed |
| EP-1362034-A1 | QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS ANTAGONISTS OF THE GONADOTROPIN-RELEASING HORMONE | Schering Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030105328-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | SCHERING AG (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002066437-A1 | QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS ANTAGONISTS OF THE GONADOTROPIN-RELEASING HORMONE | ZENTARIS GMBH (DE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004127-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | GNRHR, LHCGR, PRLHR | GABRA1 901/4885GABRB2 414/4885TRPA1 3300/4885 |
| US-20030105328-A1 | Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone | GNRHR, LHCGR, PRLHR | GABRA1 901/4885GABRB2 414/4885TRPA1 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.